Ignite Creation Date:
2025-12-25 @ 1:43 AM
Ignite Modification Date:
2026-03-08 @ 11:23 PM
Study NCT ID:
NCT01059994
Status:
COMPLETED
Last Update Posted:
2019-02-11
First Post:
2010-01-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005221', 'term': 'Fatigue'}], 'ancestors': [{'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068677', 'term': 'Sildenafil Citrate'}], 'ancestors': [{'id': 'D013449', 'term': 'Sulfonamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D013450', 'term': 'Sulfones'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D010879', 'term': 'Piperazines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'melmoore@utmb.edu', 'phone': '4097728126', 'title': 'Melinda Sheffield-Moore', 'organization': 'University of Texas Medical Branch'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Placebo Sildenafil Young', 'description': 'Sildenafil placebo: Oral, daily, 1 week.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 0, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Sildenafil Young', 'description': 'Sildenafil: oral, 25mg, daily for 1 week', 'otherNumAtRisk': 2, 'deathsNumAtRisk': 2, 'otherNumAffected': 0, 'seriousNumAtRisk': 2, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Placebo Sildenafil Older', 'description': 'Sildenafil placebo: Oral, daily, 1 week.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 0, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Sildenafil Older', 'description': 'Sildenafil: oral, 25mg, daily for 1 week', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 0, 'seriousNumAtRisk': 4, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Sildenafil Young', 'description': 'Sildenafil placebo: Oral, daily, 1 week.'}, {'id': 'OG001', 'title': 'Sildenafil Young', 'description': 'Sildenafil: oral, 25mg, daily for 1 week'}, {'id': 'OG002', 'title': 'Placebo Sildenafil Older', 'description': 'Sildenafil placebo: Oral, daily, 1 week.'}, {'id': 'OG003', 'title': 'Sildenafil Older', 'description': 'Sildenafil: oral, 25mg, daily for 1 week'}], 'classes': [{'categories': [{'measurements': [{'value': '107', 'spread': '5', 'groupId': 'OG000'}, {'value': '115', 'spread': '10', 'groupId': 'OG001'}, {'value': '54', 'spread': '31', 'groupId': 'OG002'}, {'value': '158', 'spread': '27', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.02', 'groupIds': ['OG000', 'OG001'], 'ciNumSides': 'TWO_SIDED', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'baseline to 1 week', 'description': 'Muscle fatigue was tested before and after 1 week of placebo/sildenafil (25mg/day) treatment.\n\nSubjects were asked to perform maximum effort isokinetic knee extensions until force production reached 50% of their MVC (maximum voluntary contraction). Data was collected as number of successful repetitions completed between start and 50% MVC.\n\nData is presented as percent change in repetitions (1 week of treatment / baseline).', 'unitOfMeasure': 'percent change of successful repetitions', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Protein Synthesis Rate After 1 Week of Sildenafil or Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Sildenafil Young', 'description': 'Sildenafil placebo: Oral, daily, 1 week.'}, {'id': 'OG001', 'title': 'Sildenafil Young', 'description': 'Sildenafil: oral, 25mg, daily for 1 week'}, {'id': 'OG002', 'title': 'Placebo Sildenafil Older', 'description': 'Sildenafil placebo: Oral, daily, 1 week.'}, {'id': 'OG003', 'title': 'Sildenafil Older', 'description': 'Sildenafil: oral, 25mg, daily for 1 week'}], 'classes': [{'categories': [{'measurements': [{'value': '0.06', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '0.04', 'groupId': 'OG001'}, {'value': '0.04', 'spread': '0.01', 'groupId': 'OG002'}, {'value': '0.10', 'spread': '0.03', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.004', 'groupIds': ['OG000', 'OG001'], 'ciNumSides': 'TWO_SIDED', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': '1 week', 'description': 'Skeletal muscle protein synthesis, measured as the fractional synthesis rate (the percent of the total synthesized per unit time) after 1 week of either Placebo or Sildenafil (25 mg/day). Example: if FSR = 0.06 hr-1 it means that 6% of proteins in a given sample were synthesized in the last hour or proteins is synthesized at 6% per hour. A higher rate means that more synthesis is occurring.', 'unitOfMeasure': 'fraction of proteins synthesized/hr', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Sildenafil Placebo Young', 'description': 'Sildenafil placebo: Oral, daily, 1 week.'}, {'id': 'FG001', 'title': 'Sildenafil Young', 'description': 'Sildenafil: oral, 25mg, daily for 1 week'}, {'id': 'FG002', 'title': 'Sildenafil Placebo Older', 'description': 'Sildenafil placebo: Oral, daily, 1 week.'}, {'id': 'FG003', 'title': 'Sildenafil Older', 'description': 'Sildenafil: oral, 25mg, daily for 1 week'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '4'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '3'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'Males in the age groups of 20-35 and 60-80 were recruited. Subjects were screened and enrolled at the University of Texas Medical Branch in the Institute for Translational Sciences Clinical Research Center (ITS-CRC).', 'preAssignmentDetails': 'Participants who failed screening, did not otherwise meet inclusion criteria, or decided not to participate were excluded before being assigned to intervention groups.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '12', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo Sildenafil Young', 'description': 'Sildenafil placebo: Oral, daily, 1 week.'}, {'id': 'BG001', 'title': 'Sildenafil Young', 'description': 'Sildenafil: oral, 25mg, daily for 1 week'}, {'id': 'BG002', 'title': 'Placebo Sildenafil Older', 'description': 'Sildenafil placebo: Oral, daily, 1 week.'}, {'id': 'BG003', 'title': 'Sildenafil Older', 'description': 'Sildenafil: oral, 25mg, daily for 1 week'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'categories': [{'measurements': [{'value': '25', 'spread': '6', 'groupId': 'BG000'}, {'value': '29', 'spread': '4', 'groupId': 'BG001'}, {'value': '63', 'spread': '5', 'groupId': 'BG002'}, {'value': '74', 'spread': '4', 'groupId': 'BG003'}, {'value': '51', 'spread': '23', 'groupId': 'BG004'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '12', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 12}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2010-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-11', 'completionDateStruct': {'date': '2013-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-02-06', 'studyFirstSubmitDate': '2010-01-28', 'resultsFirstSubmitDate': '2015-09-25', 'studyFirstSubmitQcDate': '2010-01-29', 'lastUpdatePostDateStruct': {'date': '2019-02-11', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2015-11-18', 'studyFirstPostDateStruct': {'date': '2010-02-01', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2015-12-23', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil', 'timeFrame': 'baseline to 1 week', 'description': 'Muscle fatigue was tested before and after 1 week of placebo/sildenafil (25mg/day) treatment.\n\nSubjects were asked to perform maximum effort isokinetic knee extensions until force production reached 50% of their MVC (maximum voluntary contraction). Data was collected as number of successful repetitions completed between start and 50% MVC.\n\nData is presented as percent change in repetitions (1 week of treatment / baseline).'}], 'secondaryOutcomes': [{'measure': 'Protein Synthesis Rate After 1 Week of Sildenafil or Placebo', 'timeFrame': '1 week', 'description': 'Skeletal muscle protein synthesis, measured as the fractional synthesis rate (the percent of the total synthesized per unit time) after 1 week of either Placebo or Sildenafil (25 mg/day). Example: if FSR = 0.06 hr-1 it means that 6% of proteins in a given sample were synthesized in the last hour or proteins is synthesized at 6% per hour. A higher rate means that more synthesis is occurring.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['fatigue', 'aging'], 'conditions': ['Fatigue', 'Aging']}, 'descriptionModule': {'briefSummary': 'This is a pilot study funded by the National Institutes of Health. In this project, we will investigate the potential effect of skeletal muscle nitric oxide (NO) production on muscle strength and physical function in older individuals. We propose to test a new method that may enable simultaneous determination of both vascular and skeletal muscle NO production for the first time in humans. Further, we will determine whether augmentation of NO-mediated responses, by administration of sildenafil citrate (Viagra), reduces fatigue and fatigability in older individuals.', 'detailedDescription': 'Fatigue is highly prevalent and associated with future mortality in older individuals. Even in non-disabled older persons, fatigue may be the primary reason for activity limitation. However, understanding the etiology of fatigue in this population has been hampered by differing or imprecise definitions of fatigue. As a result, the term fatigue has been proposed to refer to the subjective experience of tiredness or lack of energy, whereas the term fatigability should refer to the susceptibility to fatigue induced by activity of any kind (mental, physical, etc). Skeletal muscle activity can contribute to the perception of overall fatigue as well as produce a type of localized fatigue within skeletal muscle. Skeletal muscle fatigue is defined as a decline in skeletal muscle performance resulting from muscle activity.\n\nWe hypothesize that skeletal muscle NO-mediated responses are reduced with aging due to decreased skeletal muscle NO production. NO is well-known to elicit vasodilation through stimulation of cGMP signaling, and NO-mediated changes in muscle perfusion may influence both skeletal muscle and overall fatigue. To measure skeletal muscle NO production, we will infuse a stable isotope tracer of arginine, the precursor of NO, and measure its conversion across the leg and in skeletal muscle to citrulline (which is another product of the reaction that produces NO). If successful, this method will allow the study of relative changes in vascular and muscle NO production that occur with aging and other conditions (e.g., hypertension, Duchenne muscular dystrophy). We will also determine whether age-related differences in muscle perfusion and NO-cGMP signaling exist between younger and older groups. As impaired redox homeostasis and ryanodine receptor S-nitrosylation and phosphorylation have been implicated in skeletal muscle fatigue, we will assess skeletal muscle redox homeostasis and ryanodine receptor S-nitrosylation in these experiments. We hypothesize that aging will shift muscle redox homeostasis to a more oxidized state.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '20 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* 1\\. Age 20-35 yrs, and 60-80 yrs.\n* 2\\. Ability to sign consent form (score \\>23 on the 30-item Mini Mental State Examination, MMSE)\n* 3\\. Stable body weight for at least 3 months\n\nExclusion Criteria:\n\n* 1\\. Physical dependence or frailty (impairment in any of the Activities of Daily Living (ADL), history of falls (\\>2/year) or significant weight loss in the past year)\n* 2\\. Exercise training (\\>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)\n* 3\\. Pregnancy\n* 4\\. Significant heart, liver, kidney, blood or respiratory disease\n* 5\\. Peripheral vascular disease\n* 6\\. Diabetes mellitus or other untreated endocrine disease\n* 7\\. Active cancer\n* 8\\. Use of nitrates\n* 9\\. Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.\n* 10\\. Alcohol or drug abuse\n* 11\\. Severe depression (\\>5 on the 15-item Geriatric Depression Scale, GDS)\n* 12\\. Cardiac abnormalities such as a cardiac shunt or previously diagnosed pulmonary hypertension.\n* 13\\. Systolic blood pressure \\<100 or \\>150, diastolic blood pressure \\<60 or \\>90.'}, 'identificationModule': {'nctId': 'NCT01059994', 'briefTitle': 'Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability', 'organization': {'class': 'OTHER', 'fullName': 'The University of Texas Medical Branch, Galveston'}, 'officialTitle': 'Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability', 'orgStudyIdInfo': {'id': '09-213'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'placebo sildenafil young', 'description': 'Younger subjects (ages 20-35) were administered placebo sildenafil orally daily for 1 week.', 'interventionNames': ['Drug: Placebo sildenafil']}, {'type': 'EXPERIMENTAL', 'label': 'sildenafil young', 'description': 'Younger subjects (ages 20 -35) were administered sildenafil daily (25 mg/day) orally for 1 week.', 'interventionNames': ['Drug: Sildenafil']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'placebo sildenafil older', 'description': 'Older subjects (ages 60-80) were administered placebo sildenafil orally daily for 1 week.', 'interventionNames': ['Drug: Placebo sildenafil']}, {'type': 'EXPERIMENTAL', 'label': 'sildenafil older', 'description': 'Older subjects (ages 60 - 80) were administered sildenafil daily (25 mg/day) orally for 1 week.', 'interventionNames': ['Drug: Sildenafil']}], 'interventions': [{'name': 'Placebo sildenafil', 'type': 'DRUG', 'otherNames': ['Viagra'], 'description': 'Oral, daily, 1 week.', 'armGroupLabels': ['placebo sildenafil older', 'placebo sildenafil young']}, {'name': 'Sildenafil', 'type': 'DRUG', 'otherNames': ['Viagra'], 'description': 'oral, 25mg, daily for 1 week', 'armGroupLabels': ['sildenafil older', 'sildenafil young']}]}, 'contactsLocationsModule': {'locations': [{'zip': '77555', 'city': 'Galveston', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas Medical Branch', 'geoPoint': {'lat': 29.30135, 'lon': -94.7977}}], 'overallOfficials': [{'name': 'William Durham, Ph.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Texas'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'The University of Texas Medical Branch, Galveston', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}